Pasar al contenido principal

Información de salud pública más reciente de los CDC

Clinicalinfo.HIV.gov logo.
En afiliación con HIV.gov
Main navigation
  • Inicio
  • Sobre Clinicalinfo
  • Guías
  • Medicamentos
  • Glosario
  • Noticias
  • Aplicación móvil
  • Recursos
  • Contáctenos
  • Español (Spanish)
  • English
  1. Inicio
  2. Appendix D: Key to Acronyms

Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Version:
Brief Full
What's New Guidelines Panel Members Financial Disclosure Introduction Maternal HIV Testing and Identification of Perinatal HIV Exposure Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods
Overview
Reproductive Options When One or Both Partners Have HIV
Overview
Initial Evaluation and Continued Monitoring of HIV-Related Assessments During Pregnancy
Antiretroviral Drug Resistance and Resistance Testing in Pregnancy
Overview
Use of Antiretroviral Drugs to Prevent Perinatal HIV Transmission and Improve Maternal Health
Antiretroviral Therapy for People With HIV Who Are Trying to Conceive
Pregnant People With HIV Who Have Never Received Antiretroviral Drugs (Antiretroviral-Naive)
People With HIV Who Are Taking Antiretroviral Therapy When They Become Pregnant
Pregnant People With HIV Who Have Previously Received Antiretroviral Medications but Are Not Currently on Antiretroviral Medications
Pregnant People Who Have Not Achieved Viral Suppression on Antiretroviral Therapy
Table 6. What to Start: Initial Antiretroviral Regimens During Pregnancy for People Who Are Antiretroviral-Naive
Table 7. Situation-Specific Recommendations for Use of ARVs
Teratogenicity
Antiretroviral Drug Regimens and Maternal and Neonatal Outcomes
Hepatitis B Virus/HIV Coinfection
Hepatitis C Virus/HIV Coinfection
HIV-2 Infection and Pregnancy
Prenatal Care, Antiretroviral Therapy, and HIV Management in People with Perinatal-Acquired HIV Infection
Perinatal HIV Prevention for Transgender and Gender-Diverse People Assigned Female at Birth
Early (Acute and Recent) HIV Infection
Intrapartum Care for People with HIV Postpartum Follow-Up of People with HIV Infant Feeding for Individuals with HIV in the United States
Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection
Diagnosis of HIV in Infants and Children
Initial Postnatal Management of the Neonate Exposed to HIV
Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs
Appendix A: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission
Table 14. ARV Drug Use in Pregnant People With HIV | Overview
Abacavir (Ziagen, ABC)
Emtricitabine (Emtriva, FTC)
Lamivudine (Epivir, 3TC)
Tenofovir Alafenamide (Vemlidy, TAF)
Tenofovir Disoproxil Fumarate (Viread, TDF)
Zidovudine (Retrovir, ZDV)
Doravirine (Pifeltro, DOR)
Efavirenz (Sustiva, EFV)
Etravirine (Intelence, ETR)
Nevirapine (Viramune, NVP)
Rilpivirine (Edurant, RPV)
Atazanavir (Reyataz, ATV)
Darunavir (Prezista, DRV)
Lopinavir/Ritonavir (Kaletra, LPV/r)
Fostemsavir (Rukobia, FTR)
Ibalizumab-uiyk (Trogarzo, IBA)
Maraviroc (Selzentry, MVC)
Bictegravir (BIC)
Cabotegravir (CAB)
Dolutegravir (Tivicay, DTG)
Elvitegravir (EVG)
Raltegravir (Isentress, Isentress HD, RAL)
Cobicistat (Tybost, COBI)
Ritonavir (Norvir, RTV)
Overview
Amprenavir (Agenerase, APV)
Delavirdine (Rescriptor, DLV)
Didanosine (Videx, ddI)
Enfuvirtide (Fuzeon, T-20)
Fosamprenavir (Lexiva, FPV)
Indinavir (Crixivan, IDV)
Nelfinavir (Viracept, NFV)
Saquinavir (Invirase, SQV)
Stavudine (Zerit, d4T)
Tipranavir (Aptivus, TPV)
Zalcitabine (Hivid, ddC)
Antiretroviral Pregnancy Registry
Appendix C: Antiretroviral Counseling Guide for Health Care Providers
Drug Name Abbreviations
General Terms
Study and Trial Names

Download Guidelines

  • Section OnlyPDF (102.56 KB)
  • Full GuidelinePDF (6.43 MB)
  • Recommendations OnlyPDF (419.43 KB)
  • Tables OnlyPDF (906.17 KB)

Related Content

  • Clinicalinfo Drug Database
  • HIVinfo Fact Sheets: Preventing Perinatal Transmission of HIV
  • HIVinfo Fact Sheets: HIV Medicines During Pregnancy and Childbirth
  • HIVinfo Fact Sheets: Protecting Baby from HIV
  • AETC National HIV Curriculum
  • How to Cite These Guidelines
  • Perinatal Archived Guidelines

Appendix D: Key to Acronyms

Actualizado 31/01/2023 - 12:00 Reviewed Ene. 31, 2023

Download Guidelines

  • Section OnlyPDF (102.56 KB)
  • Full GuidelinePDF (6.43 MB)
  • Recommendations OnlyPDF (419.43 KB)
  • Tables OnlyPDF (906.17 KB)

Related Content

  • Clinicalinfo Drug Database
  • HIVinfo Fact Sheets: Preventing Perinatal Transmission of HIV
  • HIVinfo Fact Sheets: HIV Medicines During Pregnancy and Childbirth
  • HIVinfo Fact Sheets: Protecting Baby from HIV
  • AETC National HIV Curriculum
  • How to Cite These Guidelines
  • Perinatal Archived Guidelines

Conéctese con nosotros

Twitter
Instagram
Suscribir

Footer menu

  • Inicio
  • Sobre Clinicalinfo
  • Guías
  • Medicamentos
  • Glosario
  • Noticias
  • Aplicación móvil
  • Recoursos
  • Contáctenos
  • Declaración de privacidad
  • Patrocinadores
  • Aviso de no discriminación
  • El descargo de responsabilidad
  • Accesibilidad
  • HHS Vulnerability Disclosure

External links

  • HIVinfo.NIH.gov
  • HHS.gov
  • NIH.gov
  • Players & Viewers
  • HHS 508
  • HHS Privacy Policy
  • Whitehouse.gov
  • USA.gov
  • Ley de Acceso a Información

Proporcionado en colaboración con la Oficina de Investigación del SIDA de los NIH.